G02.2A Transport Office of the Medical Director TRANSPORT TO THE COMPREHENSIVE STROKE CENTER (HSC) Implementation date October 30, 2018

Transcription

1 G02.2A Transport Office of the Medical Director Basic TRANSPORT TO THE COMPREHENSIVE STROKE CENTER (HSC) Implementation date October 30, years & older Primary Intermediate Advanced Critical Initiate transport towards HSC Will the transport duration to HSC exceed 90 minutes? No Yes Contact the STARS TP for possible HEMS intercept before calling neurologist Continue transport directly to HSC Transport as directed Contact the HSC stroke neurologist at as soon as possible Assist as required to ensure appropriate pre-arrival consultation and notification First notification of HSC ED staff as soon as possible Ensure second notification of stroke neurologist 30 minutes prior to arrival If estimated time of arrival changes during transport, ensure notification of neurologist and ED staff Second notification of HSC ED staff 10 minutes prior to arrival G02.2A Stroke Transport HSC Page 1

2 INDICATIONS: A patient with a known or suspected acute stroke who is not eligible for fibrinolytic therapy, but may be a candidate for thrombectomy, and can arrive at HSC within 6 hours of stroke onset. CONTRAINDICATIONS: None NOTES: The Health Sciences Center (HSC) is the comprehensive stroke center for Manitoba. Contact the stroke neurologist through the paging operator at Ask to speak to the stroke neurologist on-call and inform the operator that it is for a stroke-25 outside call. Table A contains the clinic information that will be required when consulting with the stroke neurologist and additional historical information that may be required to determine suitability for therapy. Transport time must be estimated based on safe vehicular speed. Non-clinical issues that could affect patient, provider and public safety, such as road and weather conditions, are at the discretion of the vehicle operator. To minimize the patient s transport time, the STARS transport physician (TP) may advise an intercept with helicopter EMS (HEMS) at an appropriate location. Transport or redirect as advised by the TP. G02.2A Stroke Transport HSC Page 2

3 Table A: Required information Initial information (to determine destination): Patient age & gender Time of stroke onset o Is it self-reported or witnessed? Symptom(s) or sign(s) suspicious for / consistent with stroke Anticoagulation (see table B) o If the patient is on warfarin, is the INR known for certainty and, if so, what is it? Estimated transport time to HSC Advanced health care directive (yes, no or unknown) o If the patient has a directive, what level of care is directed? Identifying information (required to access prior medical records): Patient name Personal health information number (PHIN) from MHSAL health card Date of birth Initial clinical assessment Vital signs, including point-of-care glucose LAMS score (see table C) Focused neurological examination for stroke - note right or left: o Level of consciousness (alert, responds to voice, responds to pain or unresponsive) o Speech (normal, slurred, incomprehensible or mute) o Smile (normal, partial droop or complete droop) o Arm strength (normal, slow drift or rapid fall) o Hand grip strength (normal, weak or absent) o Leg strength (normal, slow drift or rapid fall) Medical history (obtain as much detail as possible): Has the patient had a seizure within the last 24 hours? Does the patient have a bleeding or clotting disorder? What other health conditions does the patient have? What medications does the patient take? Is the patient allergic to any medication or substance? When did the patient last eat? G02.2A Stroke Transport HSC Page 3

4 Table B: Anticoagulants ORAL Generic Name Canadian Name American Name Apixiban ELIQUIS ELIQUIS Betrixiban Not available in Canada BEVYXXA Dabigatran PRADAXA PRADAXA Edoxaban LIXIANA LIXIANA Rivaroxaban XARELTO XARELTO Warfarin COUMADIN JANTOVEN INJECTABLE Generic Name Canadian Name American Name Dalteparin FRAGMIN FRAGMIN Danaparoid ORGARAN ORGARAN Enoxaparin LOVENOX LOVENOX Fondaparinux ARIXTRA ARIXTRA Nadroparin FRAXIPARINE FRAXIPARINE Tinzaparin INNOHEP INNOHEP Unfractionated heparin HEPARIN HEPARIN G02.2A Stroke Transport HSC Page 4

5 Table C: Los Angeles Motor Scale (LAMS) Score Facial droop Arm drift Grip strength Absent Normal or no facial asymmetry 0 Present Partial or complete drooping of lower face 1 Absent Normal or no drift 0 Drifts down Does not fall within 10 seconds 1 Falls down Cannot be held up against gravity or falls within 10 seconds 2 Normal Normal 0 Weak grip Some movement but weak 1 No grip No visible movement (contraction may be seen but movement is absent) Total Range = 0 to 5 Step #1: If there is no obvious facial droop, ask the patient to smile. Step #2: Ask the patient to hold up both arms with the palms facing downward. If lying down, ask them to raise both arms to 45 degrees. Step #3: Ask them to grasp your index and middle finger to assess their grip strength. 2 G02.2A Stroke Transport HSC Page 5